纽脉医疗完成数千万美金B轮融资，奥博资本投资

国内领先的二尖瓣介入治疗企业上海纽脉医疗科技有限公司（以下简称“纽脉医疗”）成功完成数千万美金B轮融资，由奥博资本(OrbiMed)投资，浩悦资本担任独家财务顾问。本轮融资资金将用于推进国内首款二尖瓣置换介入瓣膜的临床及注册上市。

Neurelis Announces Commercial Availability of VALTOCO® (Diazepam Nasal Spray) for Seizure Cluster Rescue

- VALTOCO is the first and only nasal spray treatment for seizure cluster rescue in adult and pediatric patients 6 years of age and older
- Copay and patient assistance program to be provided by Neurelis for eligible VALTOCO patients

Human Longevity's Largest Study of Its Kind Shows Early Detection of Disease and Disease Risks in Adults

• Study participants were evaluated with Human Longevity's multi-modal precision health platform, the Health Nucleus™
• The assessment yielded highly actionable findings, most of which were not previously known, resulting in early identification of disease and disease risk in conditions that can lead to pre-mature mortality in adults
• Study published in the Journal Proceedings of the National Academy of Sciences

Neurelis Announces FDA Approval for Seizure Rescue Treatment VALTOCO® (Diazepam Nasal Spray) that Incorporates the Science of Intravail® for Consistent and Reliable Absorption

-- VALTOCO (diazepam nasal spray) is approved by the U.S. Food and Drug Administration (FDA) for use by a care partner outside of the medical setting for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern

-- VALTOCO is the first nasal spray approved by the FDA as a rescue treatment for people with epilepsy aged 6 and older

-- VALTOCO's proprietary formulation including Intravail® has been shown to be generally safe and well tolerated

-- VALTOCO granted Orphan Drug Exclusivity by the FDA

NeoGenomics Acquires Oncology Division from Human Longevity for $37 Million

Significantly Enhances Next Generation Sequencing Capabilities for Pharmaceutical Customers

晨泰医药在研药品Zorifertinib专家顾问会议在沪召开

2020年1月3日，晨泰医药科技有限公司主导在研产品（AZD3759）的化学名Zorifertinib及该研究命名仪式日前在上海隆重举行。